Today, Camelot Portfolios LLC sells partial stakes of Astrazeneca PLC (AZN)

Today, Camelot Portfolios LLC sells partial stakes of Astrazeneca PLC (AZN)

Camelot Portfolios LLC reduced its stake in Astrazeneca PLC (NYSE:AZN) by 18.3% during the third quarter, Holdings Channel reports. The firm owned 6,700 shares of the company’s stock after selling 1,500 shares during the period. Camelot Portfolios LLC’s holdings in Astrazeneca PLC were worth $220,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Interstate Bank raised its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the last quarter. Synovus Financial Corp raised its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the last quarter. Fifth Third Bancorp raised its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the last quarter. Integrated Investment Consultants LLC raised its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Astrazeneca PLC by 2,056.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,982 shares of the company’s stock valued at $150,000 after buying an additional 4,751 shares during the last quarter. Institutional investors own 11.81% of the company’s stock.

Astrazeneca PLC (NYSE:AZN) opened at 26.37 on Friday. The company has a market cap of $66.72 billion, a P/E ratio of 27.06 and a beta of 0.83. Astrazeneca PLC has a 52 week low of $25.88 and a 52 week high of $35.04. The firm’s 50 day moving average is $29.20 and its 200-day moving average is $30.75.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 31.30%. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.95 billion. During the same period in the previous year, the firm posted $1.03 EPS. The business’s quarterly revenue was down 2.6% on a year-over-year basis. On average, analysts predict that Astrazeneca PLC will post $3.02 earnings per share for the current fiscal year.

AZN has been the subject of several analyst reports. Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research report on Thursday, July 28th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research report on Sunday, July 31st. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a research report on Thursday, August 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Astrazeneca PLC currently has an average rating of “Hold” and an average price target of $37.61.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Related posts

Leave a Comment